Citadel Advisors’s Kindred Biosciences, Inc. KIN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-16,369
| Closed | -$150K | – | 15279 |
|
|
2021
Q2 | $150K | Sell |
16,369
-47,694
| -74% | -$277K | ﹤0.01% | 12510 |
|
|
2021
Q1 | $318K | Buy |
64,063
+12,164
| +23% | +$58.7K | ﹤0.01% | 10726 |
|
|
2020
Q4 | $224K | Sell |
51,899
-25,706
| -33% | -$105K | ﹤0.01% | 9569 |
|
|
2020
Q3 | $332K | Buy |
77,605
+38,307
| +97% | +$160K | ﹤0.01% | 7962 |
|
|
2020
Q2 | $176K | Buy |
39,298
+16,161
| +70% | +$72.2K | ﹤0.01% | 8623 |
|
|
2020
Q1 | $93K | Buy |
+23,137
| New | +$197K | ﹤0.01% | 8680 |
|
|
2019
Q1 | – | Sell |
-13,453
| Closed | -$147K | – | 10128 |
|
|
2018
Q4 | $147K | Sell |
13,453
-13,287
| -50% | -$167K | ﹤0.01% | 8072 |
|
|
2018
Q3 | $373K | Buy |
26,740
+6,243
| +30% | +$84.5K | ﹤0.01% | 7209 |
|
|
2018
Q2 | $218K | Buy |
+20,497
| New | +$200K | ﹤0.01% | 7756 |
|
|
2015
Q1 | – | Sell |
-16,138
| Closed | -$120K | – | 8978 |
|
|
2014
Q4 | $120K | Buy |
+16,138
| New | +$137K | ﹤0.01% | 6493 |
|
|
2014
Q2 | – | Sell |
-8,385
| Closed | -$155K | – | 8445 |
|
|
2014
Q1 | $155K | Buy |
+8,385
| New | +$160K | ﹤0.01% | 5770 |
|
Other funds holding KIN
Citadel Advisors's KIN Position: Q3 2021 in Review
Citadel Advisors sold out of Kindred Biosciences, Inc. (KIN) in Q3 2021, closing a stake of 16,369 shares — an estimated $150K sold.
Citadel Advisors first reported a position in KIN in Q1 2014 and held it in 11 quarters. The position peaked at $373K in Q3 2018. 1 fund tracked by Wall St. Rank holds KIN as of Q3 2021.
- Citadel Advisors reported no remaining Kindred Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
- Citadel Advisors sold 16,369 Kindred Biosciences, Inc. shares in Q3 2021, an estimated $150K.
- Citadel Advisors first reported a position in Kindred Biosciences, Inc. in Q1 2014 and held it in 11 quarters.
- Citadel Advisors's Kindred Biosciences, Inc. position peaked at $373K in Q3 2018.
- 1 fund tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2021.
Based on Citadel Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.